Weiwei Wang - Ihuman Chief Financial Officer, Director
| IH Stock | USD 1.55 0.09 5.49% |
Director
Weiwei Wang is Chief Financial Officer, Director of Ihuman Inc since 2020.
| Age | 46 |
| Tenure | 4 years |
| Address | Building B, Beijing, China, 100102 |
| Phone | 86 10 5780 6606 |
| Web | https://www.ihuman.com |
Ihuman Management Efficiency
The company has Return on Asset (ROA) of 0.0456 % which means that for every $100 of assets, it generated a profit of $0.0456. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1479 %, which means that it produced $0.1479 on every 100 dollars invested by current stockholders. Ihuman's management efficiency ratios could be used to measure how well Ihuman manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Ihuman's Return On Tangible Assets are increasing as compared to previous years. The Ihuman's current Return On Assets is estimated to increase to 0.13, while Return On Capital Employed is projected to decrease to 0.16. As of now, Ihuman's Asset Turnover is decreasing as compared to previous years.Similar Executives
| Found 1 records | DIRECTOR Age | ||
| Xuchun Luo | Huize Holding | 54 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0456 |
Ihuman Inc Leadership Team
Elected by the shareholders, the Ihuman's board of directors comprises two types of representatives: Ihuman inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ihuman. The board's role is to monitor Ihuman's management team and ensure that shareholders' interests are well served. Ihuman's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ihuman's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wendy Hayes, Independent Director | ||
| Yufeng Chi, Chairman of the Board | ||
| Wenbin Lu, Chief Technology Officer | ||
| Peng Dai, Chief Executive Officer, Director | ||
| Xuenan Li, Independent Director | ||
| Hanfeng Chi, Director | ||
| Weiwei Wang, Chief Financial Officer, Director |
Ihuman Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ihuman a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0456 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | (74.4 M) | ||||
| Shares Outstanding | 23.57 M | ||||
| Shares Owned By Institutions | 0.61 % | ||||
| Number Of Shares Shorted | 4.44 K | ||||
| Price To Earning | 7.83 X | ||||
| Price To Book | 0.65 X |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ihuman Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Hotels, Restaurants & Leisure space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ihuman. If investors know Ihuman will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ihuman listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.40) | Earnings Share (0.16) | Revenue Per Share 18.263 | Quarterly Revenue Growth (0.11) | Return On Assets 0.0456 |
The market value of Ihuman Inc is measured differently than its book value, which is the value of Ihuman that is recorded on the company's balance sheet. Investors also form their own opinion of Ihuman's value that differs from its market value or its book value, called intrinsic value, which is Ihuman's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ihuman's market value can be influenced by many factors that don't directly affect Ihuman's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ihuman's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ihuman is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ihuman's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.